Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response and antibody persistence after Japanese encephalitis vaccination in adults
jRCT1040260097Recruiting
- Sponsor
- KM Biologics
- Start
- Jul 2026
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Japanese encephalitis vaccine in Japanese encephalitis (JE), sponsored by KM Biologics. Primary endpoints: Neutralizing antibody seropositivity rate before vaccination, Neutralizing antibody titer before vaccination and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
Japanese encephalitis vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on jRCT1040260097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040260097.